Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,623.44
(
0.20%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 133391

Thursday, 01/12/2012 12:49:58 PM

Thursday, January 12, 2012 12:49:58 PM

Post# of 257443
White lie from ONTY’s CEO:

http://www.reuters.com/article/2012/01/11/us-healthcare-oncothyreon-idUSTRE80A24F20120111

“We would be perfectly content if the decision is to continue the [Stimuvax] trial to its end,” Kirkman said.

In truth, he will be disappointed if this should happen. Failure of Stimuvax to hit the success threshold in the second interim analysis would further narrow the window for the best-case scenario in which Stimuvax shows extraordinarily strong efficacy.

p.s. I have a 5% ONTY position in the SI Charity Contest.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today